Connect with us

News

Johnson Electric Reports Results for The Half Year Ended 30 September 2020

gbafNews28

Highlights of FY20/21 Half-Year Results

 

  • Group sales US$1,330 million — down 15% compared to first half of the prior financial year
  • Gross profit US$300 million or 22.5% of sales (compared to US$357 million or 22.8% of sales in prior half year)
  • Underlying EBITA margins, adjusted to exclude the impact of significant non-cash and divested items, increased to 10.2% from 9.9% in prior half year
  • Net profit attributable to shareholders decreased by 38% to US$101 million or 11.27 US cents per share on a fully diluted basis
  • Underlying net profit, excluding the net impact of significant non-cash and divested items, decreased by 7% to US$98 million
  • Free cash flow from operations US$68 million (compared to US$90 million in prior half year)
  • Total debt to capital ratio of 17% and cash reserves of US$469 million as of 30 September 2020
  • Interim dividend 17 HK cents per share (2.18 US cents per share) with a scrip dividend alternative

 

HONG KONG SAR – Media OutReach – 11 November 2020 – Johnson Electric Holdings Limited (“Johnson Electric”), a global leader in electric motors and motion subsystems, today announced its results for the six months ended 30 September 2020.

 

Total Group sales for the first half of FY20/21 totalled US$1,330 million, a decrease of 15% compared to the first half of the prior financial year. Net profit attributable to shareholders decreased by 38% to US$101 million or 11.27 US cents per share on a fully diluted basis. Underlying net profit, after adjusting for the effects of a number of significant non-cash and divested items, decreased by 7% to US$98 million.

 

Sales declined significantly in April and May due to the impact of the COVID-19 pandemic, particularly on the automotive industry in Europe and the Americas. During the month of June, the Group began to experience a marked recovery in demand and this positive trend continued throughout the second fiscal quarter. By the month of September, average weekly sales and profitability levels in most parts of our business had returned to levels of a year earlier — and in several areas exceeded them.

 

Automotive Products Group

 

The Automotive Products Group (“APG”), which accounted for 75% of total Group sales, reported a 19% decrease in sales on a constant currency basis compared to the first half of the prior year. Global light vehicle industry production volumes fell by approximately 24% over the same period.

 

This overall decline in automotive industry activity reflected the progression of the COVID-19 pandemic across different geographic regions over the course of 2020, the impact of various government containment actions on production, and the consequent effects on consumer confidence and end-market vehicle sales.

 

OEM assembly plants in Europe and North America were largely shut down in the period from late March to May. Since then, production has resumed and by September, output for the month in both these regions exceeded the prior year. Nonetheless, total light vehicle production for six months to September in Europe and North America was down 36% and 35%, respectively. Over the same period, APG’s sales in constant currency to Europe and the Americas region were down by 33% and 26%, respectively.

 

The COVID-19 outbreak hit China first and government-imposed containment measures were concentrated during the period from late January to early March 2020. The country has since witnessed a quicker and, so far, more sustained return to economic and social normality than any other major economy. This was reflected in China’s passenger car production volumes for the six months to September, which were approximately 11% higher than the same period in 2019.

 

Elsewhere in Asia, however, the pandemic caused automotive industry production to decline sharply.  The output of the export-oriented car industries of Japan and Korea fell by 30% and 13%, respectively.  Emerging Asian car markets such as India, Thailand and Indonesia were hit even harder and experienced falls in vehicle output by as much as 50%. As a result, despite the recovery in China, total light vehicle production in Asia for the six months to September was down by almost 11%. Over the same period, APG’s sales in Asia were flat in constant currency terms — reflecting both China’s higher weighting in the Group’s sales mix and APG’s innovative product line that is closely aligned to the industry’s key growth drivers of emissions reduction, fuel economy and electrification.

 

Industry Products Group

 

The Industry Products Group (“IPG”), which accounted for 25% of total Group sales, reported a 2% increase in sales on a constant currency basis compared to the first half of the prior year. While the contraction in the global economy has resulted in a decline in demand from several of the wide range of market segments that IPG serves, others have prospered due to changing consumer behaviour and purchasing preferences in specific product applications.

 

For example, sales in applications such as aerospace subsystems, vending machines, professional power tools and commercial printers have all suffered as a direct result of the reduced activity in those end-markets caused by social distancing and COVID-19 containment measures. In contrast, IPG has benefitted from a surge in the consumption of more “home-centric” consumer and industrial goods.  Product applications experiencing a strong increase in sales for Johnson Electric’s precision motors, motion subsystems, switches and solenoids include coffee machines, lawn and garden products, kitchen appliances, floor care equipment, inkjet printers, medical devices and healthcare products.

 

Profitability

 

Gross profit decreased by 16% to US$300 million — which as a percentage of sales represented a slight decline from 22.8% to 22.5%. Notwithstanding the significantly reduced sales volumes of APG in the first half, the impact on the Group’s gross margin was kept to a minimum by management’s actions to reduce operating costs and to the effects of many governments subsidizing the cost of employees who were furloughed during temporary plant shut downs.

 

Group operating profits were US$122 million compared to US$192 million in the first half of the prior financial year. The reduction in reported operating income and in net profit attributable to shareholders was primarily due to the lower sales volumes and a substantial decrease in the net contribution from Other Income and Expenses. In particular, the prior year period included a US$41 million fair value gain related to the divestment of an investment property.

 

Excluding the significant non-cash items and property divestment, the net profit margin attributable to shareholders for the first half increased to 7.4% compared to 6.8% in the first half year of the prior financial year.

 

Interim Dividend

 

At the time of the prior year’s annual results announcement in May 2020, when large parts of the Group’s operations were still severely disrupted by the COVID-19 outbreak, the Board determined that it would be prudent to suspend the final dividend payment for the 2019/20 financial year. Six months on, the Group’s global manufacturing operations and commercial conditions are more stable.

 

The Board will continue to monitor developments in the months ahead, but in keeping with the encouraging recovery of the business over the course of the first half of the 2020/21 financial year, it has determined that a resumption of dividend payments to shareholders is appropriate. Accordingly, the Board has today declared an interim dividend of 17 HK cents per share, equivalent to 2.18 US cents per share (2019 interim: 17 HK cents per share). The interim dividend will be payable in cash with a scrip alternative where a 4% discount on the subscription price will be offered to shareholders who elect to subscribe for shares. Full details of the scrip dividend alternative will be set out in a circular to shareholders.

 

The interim dividend will be payable on 12 January 2021 to shareholders registered on 2 December 2020.

 

Chairman’s Comments on the Half-Year Results and Outlook

 

Commenting on the results, Dr. Patrick Wang, Chairman and Chief Executive, said, “Johnson Electric delivered satisfactory results in the six-month period ended 30 September 2020 in the context of an unprecedented global pandemic that has had a profound impact on the economies where we operate.”

 

“The resumption of an interim dividend is an acknowledgement of the Group’s improved financial status and near-term business outlook compared to how things stood in the early months of the COVID-19 pandemic. It is also a testament to the extraordinary efforts undertaken by everyone working at Johnson Electric over the past six months. Their actions and, for many, personal financial sacrifices, have helped the company navigate successfully through a period of exceptional uncertainty and operational stress.” 

 

“However, regrettably, there is no sign of plain sailing in the months ahead — for us as a business or for any other global manufacturing enterprise. Two factors, in particular, continue to have the potential to disrupt the prospects for the global economy returning to anything like a normalized pattern of cyclical growth.”

 

“Firstly, as noted earlier, the COVID-19 pandemic is far from being behind us. In the short term, it is unclear whether the resurgence of cases in many countries will lead to a re-imposition of social and economic lockdowns that could disrupt our business and operations. Until vaccines or effective treatments for the virus are found, it is also impossible to gauge the longer-term impact that the pandemic could have on unemployment, commerce, consumer confidence and economic prosperity more broadly.”

 

“Secondly, the geopolitical landscape remains highly unpredictable. There is no indication that the trade barriers put in place between the United States and China over the past four years will be lowered any time soon.”

 

“Johnson Electric is an international company whose purpose centres on improving the quality of life of everyone we touch through our innovative motion systems. This is the primary reason why we exist as a business and our strategies are directed towards meeting this goal whatever the nature of the operating environment and macro conditions.”

 

“In this respect, I remain confident that our company is positioned among the very best in our industry to continue grow and prosper over time.”

 

Dr. Wang further commented, “Our products and technology innovations are aligned with several of the major demand imperatives of our age: reducing emissions; enhancing energy efficiency; and improving safety and healthcare. Our operating model emphasizes high-speed automation, responsiveness and increasing levels of digitalization. Our customer base and manufacturing footprint is well balanced across Asia, Europe and the Americas. Last, but not least, our company is blessed with a diverse and uniquely talented team of employees working together across four continents.”

 

“Based on these significant attributes, I believe shareholders have reason to be optimistic that Johnson Electric has a robust business model that will continue to adapt and generate sustainable cash flows long into the future.”

About Johnson Electric Group

The Johnson Electric Group is a global leader in electric motors, actuators, motion subsystems and related electro-mechanical components. It serves a broad range of industries including Automotive, Smart Metering, Medical Devices, Business Equipment, Home Automation, Ventilation, White Goods, Power Tools, and Lawn & Garden Equipment. The Group is headquartered in Hong Kong and employs over 35,000 individuals in more than 23 countries worldwide.  Johnson Electric Holdings Limited is listed on The Stock Exchange of Hong Kong Limited (Stock Code: 179). For further information, please visit: www.johnsonelectric.com.

 

Forward Looking Statements

This news release contains certain forward looking statements with respect to the financial condition, results of operations and business of Johnson Electric and certain plans and objectives of the management of Johnson Electric.

 

Words such as “outlook”, “expects”, “anticipates”, “intends”, “plans”, “believe”, “estimates”, “projects”, variations of such words and similar expressions are intended to identify such forward-looking statements.  Such forward looking statements involve known and unknown risk, uncertainties and other factors which may cause the actual results or performance of Johnson Electric to be materially different from any future results or performance expressed or implied by such forward looking statements.  Such forward looking statements are based on numerous assumptions regarding Johnson Electric’s present and future business strategies and the political and economic environment in which Johnson Electric will operate in the future.

News

Sarah Cannon to Present Latest in Blood Cancer Research at the 62nd ASH Annual Meeting & Exposition

gbafNews28

Today, Sarah Cannon announced that 53 abstracts and presentations authored by Sarah Cannon experts have been selected for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting & Exposition. Held virtually December 5-8, 2020, the ASH Annual Meeting & Exposition will bring together thought leaders from across the globe to discuss innovative research in malignant and non-malignant blood cancer.

Our network of experts are excited to share the latest advancements in blood cancer research at this years ASH Annual Meeting and Exposition, including important advances in CAR T-Cell Therapy and data from innovative studies for beta thalassemia and sickle cell disease, says Fred LeMaistre, MD, Physician-in-Chief of Blood Cancers, Sarah Cannon. We look forward to virtually coming together with experts from around the world to discuss the pivotal research and cutting-edge therapies that are changing the way we treat blood cancer.

Haydar Frangoul, MD, MS, Medical Director, Pediatric Hematology/Oncology, Sarah Cannon Center for Blood Cancer at The Childrens Hospital at TriStar Centennial, will present ˜Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9“Modified CD34+ Hematopoietic Stem and Progenitor Cells during the Plenary Scientific Session on December 6 from 7-9am PST. Dr. Frangoul will also discuss this research during a press briefing as part of the 62nd ASH Annual Meeting Press Program taking place on December 5 from 9:30-10 a.m. PST.

Aravind Ramakrishnan, MD, Medical Director of Adult Blood and Marrow Transplant, Texas Transplant Institute at the Sarah Cannon Blood Cancer Center at St. Davids South Austin Medical Center, will present ˜Phase 1 Alexander Study of AUTO3, the First CD19/22 Dual Targeting CAR T Cell Therapy, with Pembrolizumab in Patients with Relapsed/Refractory (r/r) DLBCL in an oral presentation on December 7 from 9-10:30 a.m. PST.

Additionally, Ian Flinn, MD, PhD, Director of Lymphoma Research, Sarah Cannon Research Institute, will chair the Satellite Symposia ˜Addressing the Medical Need in CLL: How BTK Inhibitors Are Improving Outcomes on December 4 from 7:30-9 a.m. PST and Jesus G. Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, will participate in an Education Session on ˜The Emerging Role of Targeted Therapies and Cell Therapy in Transplant – Live Q&A on December 5 from 2-2:45 p.m. PST.

The 53 abstracts and presentations represent studies being conducted by investigators from Sarah Cannon Blood Cancer Network and Sarah Cannon Research Institute in affiliation with: Colorado Blood Cancer Institute at Presbyterian/St. Lukes Medical Center- HealthONE in Denver, Florida Cancer Specialists, Texas Oncology at Medical City Dallas in Dallas, Private Care at Guys at London Bridge Hospital in London, UK, Sarah Cannon Blood Cancer Center at Research Medical Center in Kansas City, Mo., Sarah Cannon Blood Cancer Center at St. Davids South Austin Medical Center in Austin, Texas, Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center in Nashville, Tenn., Texas Transplant Institute at Methodist Hospital in San Antonio, Texas, Tulane Medical Center in New Orleans, and University of Oklahoma Medical Center in Oklahoma City.

Additionally, ASH Annual Meeting & Exposition posters with Sarah Cannon Blood Cancer Network experts as first authors will be presented by:

  • Carlos Bachier, MD, Director of Cellular Therapy Research, Sarah Cannon Research Institute; Program Director, Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center, will present on ˜A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS) on December 5 from 7am-3:30 p.m. PST and ˜Costs and Adverse Events Associated with Ibrutinib or Ruxolitinib in Chronic Graft-Versus-Host Disease on December 7 from 7 a.m.-3:30 p.m. PST.
  • Minoo Battiwalla, MD, MS, Director of Outcomes Research, Sarah Cannon, will present on ˜Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN) on December 7 from 7 a.m.-3:30 p.m. PST.
  • Dr. Berdeja will present on ˜Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis on December 5 from 7 a.m.-3:30 p.m. PST.
  • William Donnellan, MD, Director of Leukemia/Myelodysplastic Syndrome Research, Sarah Cannon Research Institute, will present on ˜Use of Venetoclax (VEN) and Hypomethylating Agents (HMA) in Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States (US) “ Real World (RW) Response, Treatment Duration, Dose and Schedule Modifications on December 6 from 7 a.m.-3:30 p.m. PST.
  • Dr. Flinn will present on ˜Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study on December 7 from 7 a.m.-3:30 p.m. PST.
  • Henning Schade, MD, Assistant Member Physician, Colorado Blood Cancer Institute at Presbyterian/St. Lukes Medical Center “ HealthONE, will present on ˜HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma on December 5 from 7 a.m.-3:30 p.m. PST.

About The Sarah Cannon Blood Cancer Network

The Sarah Cannon Blood Cancer Network offers patients convenient, community-based access to complex blood cancer care including blood and marrow transplantation (BMT), clinical trials and innovative therapies such as CAR T-Cell Therapy. The Sarah Cannon Blood Cancer Network brings together physician-led blood cancer programs across the United States and United Kingdom and is one of the largest providers of BMT. In fact, it conducts more than 1,200 transplants annually through eight FACT/JACIE accredited transplant centers and has performed more than 14,000 transplants since inception of its first program. The Sarah Cannon Blood Cancer Network programs include Sarah Cannon Blood Cancer Center at St. Davids South Austin Medical Center in Austin, Texas, Medical City Dallas in Dallas, Colorado Blood Cancer Institute at Presbyterian/St. Lukes Medical Center- HealthONE in Denver, Sarah Cannon Blood Cancer Center at Research Medical Center in Kansas City, Mo., Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center in Nashville, Tenn., Texas Transplant Institute at Methodist Hospital in San Antonio, HCA Healthcare UK at University College Hospital, Private Care (London), Private Care at Guys at London Bridge Hospital (London) and The Christie Private Care, part of HCA Healthcare UK (Manchester). For more information about the Network and Sarah Cannons full suite of oncology services, visit sarahcannon.com.

Becca Gelman

[email protected]

Continue Reading

News

Children’s Hospital Los Angeles Offers FREE Flu Vaccination Family Clinic

gbafNews28

Childrens Hospital Los Angeles:

WHAT:

Get your free flu shot at select CHLA Specialty Care Centers. No appointment needed. Available for the whole family. www.CHLA.org/events

 

 

 

 

WHY:

The American Academy of Pediatrics, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America recommends everyone over 6 months of age receive the flu vaccine every year. With COVID-19 numbers still at dangerous levels, its now more crucial than every to be vigilant about your familys health.

 

 

 

 

WHEN:

Saturday, December 5

 

 

Saturday, December 12

 

 

Saturday, December 19

 

 

 

 

 

9 a.m. “ 3 p.m.

 

 

 

 

WHERE:

Walk-up clinic

 

  • South Bay “ 3440 Torrance Blvd., Torrance, CA 90503 (in the main lobby)

Drive-up clinics

  • Arcadia “ 468 E. Santa Clara St., Arcadia, CA 91006
  • Encino “ 5363 Balboa Blvd., Encino, CA 91316
  • Valencia “ 23838 Valencia Blvd., Valencia, CA 91355

 

(PRESS ONLY)

Lauren Song, [email protected] or 323-203-6737

Continue Reading

News

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fortress Biotech, Inc. (FBIO) Investors

gbafNews28

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Fortress Biotech, Inc. (Fortress or the Company) (NASDAQ: FBIO) securities between December 11, 2019 and October 9, 2020 inclusive (the Class Period). Fortress investors have until January 26, 2021 to file a lead plaintiff motion.

If you suffered a loss on your Fortress investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/fortress-biotech-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Fortress develops and commercializes pharmaceutical and biotechnology products. In December 2019, the Company’s majority-controlled subsidiary, Avenue Therapeutics, Inc. (“Avenue”), submitted a New Drug Application (“NDA”) for its intravenous (“IV”) Tramadol product to the U.S. Food and Drug Administration (“FDA”) for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.

On October 12, 2020, Avenue disclosed receipt of a Complete Response Letter (“CRL”) from the FDA regarding the NDA for its IV Tramadol product. Specifically, the FDA advised Avenue that “it cannot approve the application in its present form” because “IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population.” Specifically, the CRL stated: “[I]f a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic would be needed. The likely choice would be another opioid, which would result in opioid ‘stacking’ and increase the likelihood of opioid-related adverse effects.”

On this news, Fortress’s stock price fell $1.00 per share, or 23.98%, to close at $3.17 per share on October 12, 2020, thereby injuring investors.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) IV Tramadol was not safe for the intended patient population; (2) as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired Fortress securities during the Class Period, you may move the Court no later than January 26, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to¯learn more¯about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, Los Angeles

Charles H. Linehan, 310-201-9150 or 888-773-9224

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

www.glancylaw.com

[email protected]

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News12 mins ago

Sarah Cannon to Present Latest in Blood Cancer Research at the 62nd ASH Annual Meeting & Exposition

Today, Sarah Cannon announced that 53 abstracts and presentations authored by Sarah Cannon experts have been selected for presentation at...

gbafNews28 gbafNews28
News16 mins ago

Road Stud and Delineator Market is Expected to Witness Market Growth Due to the Increasing Incidents of Road Accidents | Technavio

The global road stud and delineator market size is poised to grow by USD 399.73 million during 2020-2024, progressing at...

gbafNews28 gbafNews28
News16 mins ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of K12 Inc. (LRN) Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, announces that a class action lawsuit has...

gbafNews28 gbafNews28
News16 mins ago

Global Semiconductor Alliance (GSA) Announces its 2020 Award Recipients

The Global Semiconductor Alliance (GSA) is proud to announce the award recipients honored at this years GSA Awards Virtual Ceremony...

gbafNews28 gbafNews28
News16 mins ago

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB)

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming January 12, 2021 deadline to file a lead plaintiff...

gbafNews28 gbafNews28
News16 mins ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fortress Biotech, Inc. (FBIO) Investors

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, announces that a class action lawsuit has...

gbafNews28 gbafNews28
News16 mins ago

Children’s Hospital Los Angeles Offers FREE Flu Vaccination Family Clinic

Childrens Hospital Los Angeles: WHAT: Get your free flu shot at select CHLA Specialty Care Centers. No appointment needed. Available...

gbafNews28 gbafNews28
News19 mins ago

Zynx Health Updates and Expands Its Free-of-Charge COVID-19 Clinical Decision Support

Zynx Health today announced that it has significantly expanded and updated the publicly accessible COVID-19 clinical decision support available on...

gbafNews28 gbafNews28
News32 mins ago

AM Best Posts Interactive Webinar Highlights for “How Active Risk Management Drives Better Customer Engagement”

Viewers can access highlights from an AM Best webinar sponsored by LexisNexis Risk Solutions to learn how active risk management...

gbafNews28 gbafNews28
News40 mins ago

Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World

Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication...